Clinical trials: Differentiation
Clara Cell Protein, Diagnostic Biomarker
Validation of Clara Cell Protein as a Novel Diagnostic Biomarker for the Differentiation of Cardiogenic Pulmonary Edema From Non-Cardiogenic Pulmonary Edema
This study aimed to validate the use of clara cell secretory protein (CC16) as a biomarker for differentiating between cardiogenic pulmonary edema (CPE) and non-cardiogenic pulmonary edema (NCPE).
- Conditions
- Clara Cell Protein, Diagnostic Biomarker, Differentiation, Cardiogenic Pulmonary Edema
- Trial name
- NCT07338227
- Testing
- Clara cell protein 16
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Beni-Suef University
BRCA1 Mutation, BRCA2 Mutation
Pre-Salpingo-Oophorectomy Pilot Study of MAKO 7 Device Performance
This study evaluates the ability of the MAKO 7 device to collect various cells
- Conditions
- BRCA1 Mutation, BRCA2 Mutation, Atypia Suspicious for Malignancy
- Trial name
- NCT02974842
- Testing
- MAKO 7
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- nVision Medical
Neuroendocrine Tumors
Gallium-68 Labeled LM3 PET/CT in Neuroendocrine Tumors
LM3 is a novel somatostatin receptor antagonist, while Gallium-68 DOTATATE is a typical somatostatin receptor agonist, This study is to evaluate the safety, biodistribution, dosimetry, and lesion detection ability of Gallium-68…
- Trial name
- PET (NCT04318561)
- Testing
- Gallium-68 NODAGA-LM3 PET/CT, Gallium-68 DOTA-LM3 PET/CT, Gallium-68 DOTATATE PET/CT
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking Union Medical College Hospital
Refractory Differentiated Thyroid Gland Carcinoma
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
This phase III trial compares the effect of cabozantinib versus combination dabrafenib and trametinib for the treatment of patients with differentiated thyroid cancer that does not respond to treatment (refractory) and which…
- Trial name
- NCT06475989
- Testing
- Biospecimen Collection, Cabozantinib, Computed Tomography
- Where
- 307 sites in United States
- Volunteers
- 264 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Acquired Hemophilia
An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A
To evaluate the time of response, sustained remission rate and relapse rate of CD38 monoclonal antibody (Daratumumab) combined corticosteroid in the treatment of AHA.
- Trial name
- AHA2023 (NCT05849740)
- Testing
- Daratumumab and corticosteroid treatment
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia
Drugs used in chemotherapy, such as flavopiridol, cytarabine, and mitoxantrone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b)
- Trial name
- NCT00470197
- Testing
- alvocidib, cytarabine, mitoxantrone hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Recombinant Human Thyroid Stimulating Hormone
Safety and Efficacy of Recombinant Human Thyroid Stimulating Hormone for Adjuvant Diagnosis in Patients With Locally Advanced/Metastatic Differentiated Thyroid Cancer
Exogenous injection of recombinant human thyroid stimulating hormone (rhTSH) can elevate TSH in the short term (2 days) to meet the requirements of diagnostic 131I SPECT/CT whole-body scans.
- Trial name
- NCT06431620
- Testing
- Recombinant Human Thyroid Stimulating Hormone
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer
Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery
This phase I trial is studying the side effects and best dose of iodine I 131 when given together with pazopanib hydrochloride in treating patients with recurrent and/or metastatic thyroid cancer previously treated with iodine I…
- Conditions
- Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer, Stage IVA Papillary Thyroid Cancer, Stage IVB Follicular Thyroid Cancer
- Trial name
- NCT01413113
- Testing
- pazopanib hydrochloride, iodine I 131
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Washington
Stage IV Lung Cancer
Antineoplaston Therapy in Treating Patients With Stage IV Lung Cancer
Current therapies for Stage IV Lung Cancer provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Stage IV Pancreatic Cancer.
- Trial name
- NCT00003492
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Burzynski Research Institute
Liposarcoma, Leiomyosarcoma
Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma
This is an Italian, multicentre, single arm, phase II study, with an intra-patient comparison end point. This study aims at confirming the activity of the drug trabectedin as second/further line treatment in retroperitoneal…
- Trial name
- TRAVELL (NCT02247544)
- Testing
- Trabectedin
- Where
- 21 sites in Italy
- Volunteers
- 105 people
- Sponsor
- Italian Sarcoma Group
Leukemia, Neutropenia
Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing.
- Trial name
- NCT00002658
- Testing
- filgrastim, amsacrine, cyclophosphamide
- Where
- United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Medical Research Council
Head and Neck Cancer
Head & Neck Cancer Survivorship: Physical and Functional Status
RATIONALE: Early physical therapy may be effective in improving range of motion of the neck and shoulders in head and neck cancer survivors who are undergoing chemotherapy and radiation therapy.
- Trial name
- NCT00751816
- Testing
- systemic chemotherapy, survey administration, adjuvant therapy
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Vanderbilt University
Advanced Well-differentiated Pancreatic Neuroendocrine Tumor
Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor
Temozolomide or dacarbazine-based chemotherapy combined with endostatin have efficacy in well-differentiated pancreatic neuroendocrine tumor
- Trial name
- NCT01845675
- Testing
- temozolomide or dacarbazine-based chemotherapy, endostatin
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Peking Union Medical College Hospital
Bone Marrow Ablation, Leukemia
High-Dose Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia in Remission
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Trial name
- NCT00002567
- Testing
- filgrastim, etoposide, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pathologically Confirmed Differentiated Thyroid Carcinoma, All Patients Are in the Initial Treatment Phase
The Effect of a Psychosomatic Symptom Intervention Program on the Primary Treatment of Differentiated Thyroid Cancer
The psychosomatic symptoms of patients with differentiated thyroid cancer (DTC) during the initial treatment phase need to be improved.
- Conditions
- Pathologically Confirmed Differentiated Thyroid Carcinoma, All Patients Are in the Initial Treatment Phase, Normal Cognitive and Communicative Abilities, Capable of Reading and Understanding Questionnaires in Chinese, Ability to Use a Smartphone
- Trial name
- NCT06422702
- Testing
- Psychosomatic Symptoms Intervention, Extended supportive care
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Harbin Medical University
Neuroendocrine Tumors
Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors
The variable clinical outcome of patients with G2 \& G3 well diff GEP-NETs makes the selection of an optimal treatment strategy challenging.
- Trial name
- NCT04804371
- Testing
- F18-FDG
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University Health Network, Toronto
Type 2 Diabetes, Inflammation
Targeting Risk Factors for Diabetes in Subjects With Normal Blood Cholesterol Using Omega-3 Fatty Acids
Every 3 minutes a new case of diabetes is diagnosed in Canada, mostly type 2 diabetes (T2D) increasing the risk for heart disease.
- Conditions
- Type 2 Diabetes, Inflammation, Insulin Sensitivity/Resistance, Fatty Acids, Omega-3
- Trial name
- NCT04485871
- Testing
- Omega-3 fatty acids
- Where
- Canada
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Institut de Recherches Cliniques de Montreal
Differentiated Thyroid Cancer
Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone
The goal of this study is to determine the effect of combining everolimus and sorafenib in patients with metastatic differentiated thyroid cancer who progressed on sorafenib alone.
- Trial name
- NCT01263951
- Testing
- Everolimus, Sorafenib
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Thomas Jefferson University
Locally Advanced Thyroid Gland Carcinoma, Thyroid Cancer
Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer
The current study aims to explore the potential advantages of chemotherapy that is implemented based on drug sensitivity testing.
- Trial name
- NCT06713057
- Testing
- Cyclophosphamide+Pemetrexed+5-Fluorouracil, Cyclophosphamide+Doxorubicin+5-Fluorouracil, Vindesine + Cisplatin
- Where
- China
- Volunteers
- 20 people
- Sponsor
- West China Hospital
Neuroendocrine Carcinoma
Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract
The purpose of the study is to understand the extent and degree of somatostatin receptor expression in poorly differentiated neuroendocrine carcinomas .
- Trial name
- NCT04069299
- Testing
- 68Ga-DOTATATE, Positron Emission Tomography (PET) Scan
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute